2006 Guide to psychiatric drug interactions

Sheldon H. Preskorn, David Flockhart

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Drug-drug interactions (DDIs) are a concern for the prescriber because they have the potential for causing untoward outcomes for everyone involved: morbidity and even mortality for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. Based on the 2004 Health and Human Services report, 7% of Americans >18 years of age >20% of Americans >65 years of age had taken ≥5 prescription medications in the week preceding the survey. Additional studies have found that patients on psychiatric medications, such as antidepressants, are on more medications than patients not on psychiatric medications. It is important for prescribers to appreciate that medications interact not on the basis of their therapeutic use but on the basis of their pharmacodynamics and pharmacokinetics. For these reasons, the prescriber of pyschiatric medications must consider all of the medications the patient is taking. Similar to the 2004 version, this educational review emphasizes the role of pharmacologic principles to guide the safe and effective use of multiple medications when such use is necessary. The review focuses on neuropsychiatric medications but also covers all other drugs to the extent that they interact with psychiatric medications. This review also presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.

Original languageEnglish
Pages (from-to)35-64
Number of pages30
JournalPrimary Psychiatry
Volume13
Issue number4
StatePublished - Apr 2006

Fingerprint

Drug Interactions
Psychiatry
Pharmaceutical Preparations
Pharmacokinetics
Therapeutic Uses
Antidepressive Agents
Health Services
Prescriptions
Morbidity
Delivery of Health Care
Costs and Cost Analysis
Mortality

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Genetics

Cite this

Preskorn, S. H., & Flockhart, D. (2006). 2006 Guide to psychiatric drug interactions. Primary Psychiatry, 13(4), 35-64.

2006 Guide to psychiatric drug interactions. / Preskorn, Sheldon H.; Flockhart, David.

In: Primary Psychiatry, Vol. 13, No. 4, 04.2006, p. 35-64.

Research output: Contribution to journalArticle

Preskorn, SH & Flockhart, D 2006, '2006 Guide to psychiatric drug interactions', Primary Psychiatry, vol. 13, no. 4, pp. 35-64.
Preskorn SH, Flockhart D. 2006 Guide to psychiatric drug interactions. Primary Psychiatry. 2006 Apr;13(4):35-64.
Preskorn, Sheldon H. ; Flockhart, David. / 2006 Guide to psychiatric drug interactions. In: Primary Psychiatry. 2006 ; Vol. 13, No. 4. pp. 35-64.
@article{0b504c75ff68404eae7d6085e7718fcf,
title = "2006 Guide to psychiatric drug interactions",
abstract = "Drug-drug interactions (DDIs) are a concern for the prescriber because they have the potential for causing untoward outcomes for everyone involved: morbidity and even mortality for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. Based on the 2004 Health and Human Services report, 7{\%} of Americans >18 years of age >20{\%} of Americans >65 years of age had taken ≥5 prescription medications in the week preceding the survey. Additional studies have found that patients on psychiatric medications, such as antidepressants, are on more medications than patients not on psychiatric medications. It is important for prescribers to appreciate that medications interact not on the basis of their therapeutic use but on the basis of their pharmacodynamics and pharmacokinetics. For these reasons, the prescriber of pyschiatric medications must consider all of the medications the patient is taking. Similar to the 2004 version, this educational review emphasizes the role of pharmacologic principles to guide the safe and effective use of multiple medications when such use is necessary. The review focuses on neuropsychiatric medications but also covers all other drugs to the extent that they interact with psychiatric medications. This review also presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.",
author = "Preskorn, {Sheldon H.} and David Flockhart",
year = "2006",
month = "4",
language = "English",
volume = "13",
pages = "35--64",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "4",

}

TY - JOUR

T1 - 2006 Guide to psychiatric drug interactions

AU - Preskorn, Sheldon H.

AU - Flockhart, David

PY - 2006/4

Y1 - 2006/4

N2 - Drug-drug interactions (DDIs) are a concern for the prescriber because they have the potential for causing untoward outcomes for everyone involved: morbidity and even mortality for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. Based on the 2004 Health and Human Services report, 7% of Americans >18 years of age >20% of Americans >65 years of age had taken ≥5 prescription medications in the week preceding the survey. Additional studies have found that patients on psychiatric medications, such as antidepressants, are on more medications than patients not on psychiatric medications. It is important for prescribers to appreciate that medications interact not on the basis of their therapeutic use but on the basis of their pharmacodynamics and pharmacokinetics. For these reasons, the prescriber of pyschiatric medications must consider all of the medications the patient is taking. Similar to the 2004 version, this educational review emphasizes the role of pharmacologic principles to guide the safe and effective use of multiple medications when such use is necessary. The review focuses on neuropsychiatric medications but also covers all other drugs to the extent that they interact with psychiatric medications. This review also presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.

AB - Drug-drug interactions (DDIs) are a concern for the prescriber because they have the potential for causing untoward outcomes for everyone involved: morbidity and even mortality for the patient, liability for the prescriber, and increased costs for the healthcare system. The risk of unintended and untoward DDIs is increasing in concert with both the increasing number of pharmaceuticals available and the number of patients on multiple medications. Based on the 2004 Health and Human Services report, 7% of Americans >18 years of age >20% of Americans >65 years of age had taken ≥5 prescription medications in the week preceding the survey. Additional studies have found that patients on psychiatric medications, such as antidepressants, are on more medications than patients not on psychiatric medications. It is important for prescribers to appreciate that medications interact not on the basis of their therapeutic use but on the basis of their pharmacodynamics and pharmacokinetics. For these reasons, the prescriber of pyschiatric medications must consider all of the medications the patient is taking. Similar to the 2004 version, this educational review emphasizes the role of pharmacologic principles to guide the safe and effective use of multiple medications when such use is necessary. The review focuses on neuropsychiatric medications but also covers all other drugs to the extent that they interact with psychiatric medications. This review also presents tables outlining major pharmacodynamic and pharmacokinetic mechanisms mediating DDIs relevant to the patient on psychiatric medications.

UR - http://www.scopus.com/inward/record.url?scp=33646388393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646388393&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33646388393

VL - 13

SP - 35

EP - 64

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 4

ER -